Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Assets: 2019-2025

Historic Assets for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $104.5 million.

  • Eton Pharmaceuticals' Assets rose 191.59% to $104.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.5 million, marking a year-over-year increase of 191.59%. This contributed to the annual value of $76.1 million for FY2024, which is 139.83% up from last year.
  • As of Q3 2025, Eton Pharmaceuticals' Assets stood at $104.5 million, which was up 2.79% from $101.7 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Assets registered a high of $104.5 million during Q3 2025, and its lowest value of $21.5 million during Q3 2022.
  • Over the past 3 years, Eton Pharmaceuticals' median Assets value was $31.8 million (recorded in 2024), while the average stood at $53.0 million.
  • Per our database at Business Quant, Eton Pharmaceuticals' Assets declined by 25.62% in 2022 and then spiked by 219.50% in 2025.
  • Over the past 5 years, Eton Pharmaceuticals' Assets (Quarterly) stood at $27.5 million in 2021, then fell by 8.87% to $25.0 million in 2022, then rose by 26.81% to $31.7 million in 2023, then skyrocketed by 139.83% to $76.1 million in 2024, then soared by 191.59% to $104.5 million in 2025.
  • Its last three reported values are $104.5 million in Q3 2025, $101.7 million for Q2 2025, and $84.0 million during Q1 2025.